Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 8/20 | 0.36 |
| ▸ | BCHE | P06276 | 5/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 0.34 |
| ▸ | SUV39H1 | O43463 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19657132 | 1.00 | ACHE (0.36) | ACHEBCHETACR1EHMT2SUV39H1 | |
| SCHEMBL20508875 | 1.00 | ACHE (0.36) | ACHEBCHETACR1EHMT2SUV39H1 | |
| SCHEMBL19656080 | 1.00 | ACHE (0.36) | ACHEBCHETACR1EHMT2SUV39H1 | |
| SCHEMBL19657099 | 1.00 | ACHE (0.36) | ACHEBCHETACR1EHMT2SUV39H1 | |
| SCHEMBL29386566 | 1.00 | ACHE (0.36) | ACHEBCHETACR1EHMT2SUV39H1 | |
| SCHEMBL19655967 | 1.00 | ACHE (0.36) | ACHEBCHETACR1EHMT2SUV39H1 | |
| SCHEMBL20927482 | 0.99 | TACR1 (0.36) | ACHEBCHETACR1EHMT2SUV39H1 | |
| SCHEMBL1006038 | 0.99 | TACR1 (0.36) | ACHEBCHETACR1EHMT2SUV39H1 | |
| SCHEMBL19655969 | 0.99 | TACR1 (0.36) | ACHEBCHETACR1EHMT2SUV39H1 | |
| SCHEMBL20927487 | 0.99 | TACR1 (0.36) | ACHEBCHETACR1EHMT2SUV39H1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10640508-B2 | Diazene directed modular synthesis of compounds with quaternary carbon centers | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190119286-A1 | DIAZENE DIRECTED MODULAR SYNTHESIS OF COMPOUNDS WITH QUATERNARY CARBON CENTERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119286-A1 | DIAZENE DIRECTED MODULAR SYNTHESIS OF COMPOUNDS WITH QUATERNARY CARBON CENTERS | CSPP1, CBR3, NPY2R | ACHE 1089/4885BCHE 1005/4885TACR1 1047/4885 |
| US-10640508-B2 | Diazene directed modular synthesis of compounds with quaternary carbon centers | CSPP1, CBR3, NPY2R | ACHE 1089/4885BCHE 1005/4885TACR1 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.